Role of inflammatory cytokines in depression: Focus on interleukin-1β
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
According to the World Health Organization, major depression will become the leading cause of disability worldwide by the year 2030. Despite extensive research into the mechanisms underlying this disease, the rate, prevalence and disease burden has been on the rise, particularly in the industrialized world. Epidemiological studies have shown biological and biochemical differences in disease characteristics and treatment responses in different age groups. Notable differences have been observed in the clinical presentation, co-prevalence with other diseases, interaction with the immune system and even in the outcome. Thus, there is an increased interest in characterizing these differences, particularly in terms of contribution of different factors, including age, cytokines and immunotherapy. Research into the possible mechanisms of these interactions may reveal novel opportunities for future pharmacotherapy. The aim of the present review is to document recent literature regarding the impact of inflammatory mechanisms on the pathophysiology of the depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386 · cited 1×
“Major depression is set to become the leading cause of disability worldwide by the year 2030 (1).”
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Biological basis of the behavior of sick animals
Hart, B. L. (1988) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(88)80004-6 · Cited by 2,223 · cited 2×
“Sickness behavior, first reported by Hart (12), was characterized by hyperthermia, lethargy, sleep and appetite disturbances, and reduced grooming, which arose as a consequence of an infectious stimulus.”
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?
Yudkin, J. S., Kumari, M., Humphries, S. E., & Mohamed-Ali, V. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00463-3 · Cited by 1,775
Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Ershler, W. B., & Keller, E. T. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.245 · Cited by 1,282
The Pathophysiologic Roles of Interleukin-6 in Human Disease
Papanicolaou, D. A., Wilder, R. L., Manolagas, S. C., & Chrousos, G. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-2-199801150-00009 · Cited by 1,146
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120 · cited 1×
“In another setting, a pretreatment with SSRI, paroxetine successfully prevented the onset of depressive symptoms in a significant number of patients undergoing high-dose IFN-α therapy for malignant melanoma as compared to those who were not pre-treated with the same antidepressant (66).”
Liu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
The macrophage theory of depression
Smith, R. S. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90272-z · Cited by 931 · cited 1×
“Since Smith (9) presented a study of the implications of cytokines in depressive-like behavior, establishing the etiology and pathogenesis of depression has become a point of research.”
Positive Psychology: An Introduction
Seligman, M. E. P., & Csikszentmihalyi, M. (2014) · Flow and the Foundations of Positive Psychology · doi:10.1007/978-94-017-9088-8_18 · Cited by 911
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress
Koo, J. W., & Duman, R. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708092105 · Cited by 862 · cited 1×
“A study investigating antineurogenic and anhedonic effects of stress found that many of these actions require IL-1β as the mediator and were not observed in the presence of an IL-1β antagonist (49).”
Cytokine, Sickness Behavior, and Depression
Dantzer, R. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.02.002 · Cited by 789
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Dystrophic microglia in the aging human brain
Streit, W. J., Sammons, N. W., Kuhns, A. J., & Sparks, D. L. (2004) · Glia · doi:10.1002/glia.10319 · Cited by 705
Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways
Maes, M., Berk, M., Goehler, L., Song, C., Anderson, G., Gałecki, P., & Leonard, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-66 · Cited by 629 · cited 1×
“Additionally, inflammatory disorders have been associated with alterations in behavior (6,11).”
Zhu, C.-B., Blakely, R. D., & Hewlett, W. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301029 · Cited by 549
White matter hyperintensities in late life depression: a systematic review
Herrmann, L. L., Le Masurier, M., & Ebmeier, K. P. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.124651 · Cited by 456 · cited 1×
“The presence of these hyperintensities is also associated with weakened effect of antidepressant treatment, as well as long-term disability and neuro-cognitive decline (79).”
Koprich, J. B., Reske-Nielsen, C., Mithal, P., & Isacson, O. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-8 · Cited by 355
Tissue‐specific regulation of zinc metabolism and metallothionein genes by interleukin 1
Cousins, R. J., & Leinart, A. S. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.13.2458983 · Cited by 312 · cited 1×
“Reduced levels of zinc during an episode of depression has been proposed to originate from increased levels of IL-1, which results in sequestration of metallothionen, the zinc-binding protein found in the liver (39).”
Clark, A. K., Staniland, A. A., Marchand, F., Kaan, T. K. Y., McMahon, S. B., & Malcangio, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3295-09.2010 · Cited by 291 · cited 7×
“In an in vivo experiment, where LPS induced sickness behavior in mice, it also led to an increase in the extracellular concentration of 5-hydroxytryptamine and its metabolite, 5-hydroxyindoleacetic acid in the rat hippocampus.”
InfluentialPlasma and Cerebrospinal Fluid Interleukin-6 Concentrations in Posttraumatic Stress Disorder
Baker, D. G., Ekhator, N. N., Kasckow, J. W., Hill, K. K., Zoumakis, E., Dashevsky, B. A., Chrousos, G. P., & Geracioti Jr., T. D. (2001) · Neuroimmunomodulation · doi:10.1159/000049028 · Cited by 238
Basso, A. M., Bratcher, N. A., Harris, R. R., Jarvis, M. F., Decker, M. W., & Rueter, L. E. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.10.018 · Cited by 224
Regulation of the Human Serotonin Transporter by Interleukin-1β
Ramamoorthy, S., Ramamoorthy, J. D., Prasad, P. D., Bhat, G. K., Mahesh, V. B., Leibach, F. H., & Ganapathy, V. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2659 · Cited by 156
Corwin, E. J., Johnston, N., & Pugh, L. (2008) · Biological Research For Nursing · doi:10.1177/1099800408323220 · Cited by 111 · cited 1×
“In another study, IL-1 β levels were found to be higher in women with symptoms of depression when compared with those who did not have any such symptoms 1 month post-partum (37).”
DNA microarray analysis of the aging brain
Prolla, T. A. (2002) · Chemical Senses · doi:10.1093/chemse/27.3.299 · Cited by 110 · cited 1×
“A DNA microarray analysis of the aging brain demonstrated a gene expression profile suggestive of a marked inflammatory response, oxidative stress and reduced neural plasticity and neurotrophic support (34).”
Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder
Pike, J. L., & Irwin, M. R. (2006) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2005.05.004 · Cited by 101 · cited 1×
“Natural killer cells have been found to be reduced with augmented IL-6 release during depressive episodes (18,19).”
Depression following pegylated interferon-alpha: Characteristics and vulnerability
Lotrich, F. E., Rabinovitz, M., Gironda, P., & Pollock, B. G. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.05.013 · Cited by 100 · cited 1×
“…certain studies have hypothesized that incidence of major depression remains the same in patients treated with IFN as compared to the general population (72), others indicate that major depression may be induced by the treatment, even in subjects without a previous history of major depression (73).”
Lawson, M. A., McCusker, R. H., & Kelley, K. W. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-54 · Cited by 80 · cited 6×
“In an in vivo experiment, where LPS induced sickness behavior in mice, it also led to an increase in the extracellular concentration of 5-hydroxytryptamine and its metabolite, 5-hydroxyindoleacetic acid in the rat hippocampus.”
InfluentialKelley, K. W., O’Connor, J. C., Lawson, M. A., Dantzer, R., Rodriguez-Zas, S. L., & McCusker, R. H. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.02.003 · Cited by 49 · cited 1×
“Prolonged depressive-like behavior has been documented in aged rats exposed to Bacillus Calmette‑Guérin (42,46).”
Seil, M., Ouaaliti, M. E., Abdou Foumekoye, S., Pochet, S., & Dehaye, J. (2012) · Innate Immunity · doi:10.1177/1753425910377101 · Cited by 10 · cited 7×
“In an in vivo experiment, where LPS induced sickness behavior in mice, it also led to an increase in the extracellular concentration of 5-hydroxytryptamine and its metabolite, 5-hydroxyindoleacetic acid in the rat hippocampus.”
Influential
Cited by
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review
Cortes Rivera, M., Mastronardi, C., Silva-Aldana, C., Arcos-Burgos, M., & Lidbury, B. (2019) · Diagnostics · doi:10.3390/diagnostics9030091 · Cited by 313
Selected biomarkers of depression: what are the effects of cytokines and inflammation
Harsanyi, S., Kupcova, I., Danisovic, L., & Klein, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010578 · Cited by 299
“However, their peripheral levels are also studied in association with antidepressant treatment [15,16].”
BackgroundAlli, S. R., Gorbovskaya, I., Liu, J. C. W., Kolla, N. J., Brown, L., & Müller, D. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094494 · Cited by 202
“For example, depression is associated with the release of C-reactive protein (CRP) and cytokines such as IL-1, IL-2, IL-6, IFN-γ, and IL-1β [19].”
BackgroundSerum Interferon-Gamma Level Is Associated with Drug-Naïve Major Depressive Disorder
Daria, S., Proma, M. A., Shahriar, M., Islam, S. M. A., Bhuiyan, M. A., & Islam, M. R. (2020) · SAGE Open Medicine · doi:10.1177/2050312120974169 · Cited by 46
Metadata
- Authors
- Farooq, R. K., Asghar, K., Kanwal, S., & Zulqernain, A.
- Venue
- Biomedical Reports
- Publisher
- Spandidos Publications
- Published
- 2016-11-10
- Volume
- 6
- Issue
- 1
- Pages
- 15-20
- ISSN
- 2049-9434 (ISSN-L)
- 2049-9442
- OpenAlex
- W2555082051
- Cited by
- 153
- References
- 31
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.